Lexaria Bioscience Receives Three New Patents, Grows Portfolio to 46 Granted Patents Worldwide
Lexaria Bioscience receives three new patents, expanding its portfolio to 46 granted patents worldwide. The company's DehydraTECH(TM) drug delivery platform technology offers increased bioavailability and effective oral delivery of APIs.
This news matters as it highlights the growing patent portfolio and the value of patents for biotechnology companies. It also emphasizes the potential competitive advantage and future commercial partnerships for Lexaria Bioscience.